Authors | Recommended age to commence screening (years) | Age (mean or median (range)) (years) | MMR mutation carrier status (%) | Cancers screened for | Screening method | Screening interval |
Dove-Edwin et al10 | 30–35 | UK: 40 (24–64) Netherlands: 42 (23–68) | AC: 171 Non-AC/AC-II: 98 | EC | TVUS | 1–2 years |
Rijcken et al11 | 30–35 | 37 (27–60) | MMR: 11 (27%) | EC +OC | GE+TVUS + CA-125; curettage if positive TVUS | Annually |
Renkonen-Sinisalo et al12 | 30–35 | MMR: 175 (100%) | EC +OC | Varied between institutions. GE+TVUS + CA-125 +EB | 2–3 years | |
Lecuru et al13 | Not provided | 42 | MMR: 13 (21%) AC-II: 49 (79%) | EC | EB+hysteroscopy | Annually |
Gerritzen et al14 | 30 | 46 (23–72) | MMR: 67 (67%) No mutation: 21 (21%) Unknown: 12 (12%) | EC +OC | GE+TVUS + CA-125 +ES if indicated; routine ES from 2006 | Annually |
Jarvinen et al15 | 35 | MMR carriers: 36 (18–72) Non-carriers: 42 (18–72) | MMR: 103 (100%) | EC +OC | TVUS +EB | 2–3 years |
Lecuru et al16 | 30 | 42.5 | MMR: 14 (24%) AC-II: 44 (76%) | EC | GE+TVUS + EB | Annually |
Guillen-Ponce et al17 | Not provided | Not provided | Not provided | EC | GE+TVUS; EB if TVUS abnormal | Not provided |
Bats et al18 | Not provided | 41 | Not provided | EC | GE+pelvic US+hysteroscopy; EB reference standard | Not provided |
Arts-De Jong et al28 | 30 | Not provided | MMR: 123 (87.9%) | OC | TVUS +CA-125 | Annually |
Manchanda et al19 | 30 | 43 | MMR: 16 (39%) AC-II: 25 (61%) | EC | TVUS +EB+hysteroscopy | Annually |
Stuckless et al20 | Not provided | 36 | MSH2: 54 (100%) | EC +OC | TVUS +CA-125+EB | Not provided |
Helder-Woolderink et al21 | 30 | Period I: 38 (26–61) Period II: 41 (23–67) | MMR: 44 (59%) EPCAM: 3 (4%) First degree relatives: 28 (37%) | EC +OC | TVUS +CA-125. ES and hysteroscopy if indicated, routine ES from 2008 | Annually |
Douay-Hauser et al22 | 30 | Not provided | Not provided | EC | GE+EB+TVUS±hysteroscopy | Annually |
Ketabi et al23 | 25 | 39 (19–78) | LS (family with confirmed MMR): 236 (27%) AC: 269 (31%) AC-like: 366 (42%) | EC +OC | GE+TVUS; EB+CA-125 if TVUS abnormal | 2 years |
Tzortzatos et al24 | 30 | 50 (24–84) | MMR: 45 (100%) | EC +OC | TVUS +CA-125+EB | Annually |
Gosset et al25 | Not provided | 51 | MMR: 191 (100%) | EC +OC | GE+pelvic US+EB+hysteroscopy | Annually |
Nebgen et al26 | Not provided | 39.2 (25.5–73.7) | MMR: 56 (70%) EPCAM: 1 (1%) AC-II: 23 (29%) | EC +OC | GE+EB for EC; TVUS +CA-125 for OC | Annually |
Rosenthal et al29 | 35 | Nil age range provided for MMR carriers only | MMR: 65 (100%) | OC | TVUS +CA-125 | Annually |
Rosenthal et al30 | 35 | Nil age range provided for MMR carriers only | MMR: 120 (100%) | OC | TVUS annually+CA-125 every 4 months | Annually and every 4 months |
Eikenboom et al27 | 30–35 prior to 2016 40 from 2016 | 46 (21.5–75) prior to 2016 53.8 (30–71.3) after 2016 | MMR: 164 (100%) | EC +OC | ES +TVUS +/- CA-125 | Annually |
AC, Amsterdam criteria; AC-II, Amsterdam II criteria; CA-125, cancer antigen 125; EB, endometrial biopsy; EC, endometrial cancer; ES, endometrial sampling (curettage or biopsy); GE, gynecological examination; LS, Lynch syndrome; MMR, mismatch repair; OC, ovarian cancer; TVUS, transvaginal ultrasound; US, ultrasound.